Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safimestomig Monotherapy and Combination in AML/MDS
NCT05448599Phase 2Unknown
- Sponsor
- Mabwell
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3211 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Mabwell. Status: unknown.
02
Drugs
6MW3211
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05448599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448599.